Where does Ceregate GmbH rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Ceregate GmbH ranks #25,979 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Ceregate GmbH hold?

Ceregate GmbH holds 10 US utility patents granted between 2022 and 2025, spanning 7 technology areas.

What is Ceregate GmbH's Innovation Score?

Ceregate GmbH has an Innovation Score of 50.8 out of 100 (top 12% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Ceregate GmbH focus on?

Ceregate GmbH's top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 10 patents, ranking #372 of 1,943 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Ceregate GmbH's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Ceregate GmbH.

What does claim depth mean for Ceregate GmbH's patents?

Ceregate GmbH's patents average 22.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Ceregate GmbH patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Ceregate GmbH

USPTO PatentsView assignee record - 10 granted patents across 7 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Ceregate ranks #25,979 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 7 technology areas.

#25,979
of 49,997 US assignees by volume: Top 12%
by Innovation Score (50.8/100): 22.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R25979 · Foreign Corporation #25,979 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 10 grants
MID-PACK #25,979/49,997
PHOTO-FINISH CelluComp
CPC-NARROW A61N · 7 areas
INNOV-PAR 50.8/100
CLAIMS-DENSE 22.0 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2022–2025 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: CelluComp Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Ceregate’s 50.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.3 pts (16%) Velocity 20.0 pts (39%) Breadth 9.4 pts (18%) Claim depth 13.2 pts (26%)

Qualcomm Incorporated · highest

85
Ceregate · this assignee

51
3D Lighting… · lowest

7

What this shows Ceregate's Innovation Score is 50.8/100 (top 12% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Ceregate?

Each dot is one of Ceregate’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Ceregate’s own 22.0 claims/patent is ABOVE the 10.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Ceregate vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Ceregate's grants concentrate

Ceregate GmbH is a focused PatentsView assignee: 7 CPC subclasses with 100% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2022 (3 grants) versus a trough of 1 in 2024. By volume, Ceregate sits between CelluComp Limited and Changzhou T&D International Trading Co., Ltd..

Ceregate's three-year grant acceleration

Ceregate GmbH shows 6 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Cellucomp

10
Center Rock

10
Centro De Investi…

10
Cerebral Assessme…

10
Cerro Wire

10
Chaei Hsin Enterp…

10
Chagrinovations

10
Changzhou T&D Int…

10
Ceregate ◀

10

What this shows Ceregate holds 10 patents at rank #26,027, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Ceregate

By rank, the assignees closest to #26,027 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Ceregate's primary technology class.

Ceregate's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

51 Top 12% higher than 88% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table

Ceregate GmbH patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2022	3	30.0%
2023	2	20.0%
2024	1	10.0%
2025partial year	4	40.0%

Which technologies does Ceregate GmbH patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 10

A61B - DIAGNOSIS; SURGERY; Identification 6

G06F - Electric Digital Data Processing 4

H04W - Wireless Communication Networks 1

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 1

H04L - Transmission OF Digital Information, e.g. Telegraphic Communication 1

H04B - Transmission 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Ceregate GmbH's patent record in context - here's where to go next.

Ceregate GmbH's lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 100% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #25,979 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Ceregate GmbH against CelluComp Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 50.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.